

### **Cohort Overview**

Mia M. Gaudet, Ph.D.

**Connect Chief Scientist** 

Trans Divisional Research Program
Division of Cancer Epidemiology and Genetics
National Cancer Institute



### **Study Objectives**

Comprehensive research resource using new technologies and methods for the scientific community to study:

#### **Cancer Etiology**

Precursor to Tumor Progression
Cancer Risk Prediction
Early Detection of Cancer
Survivorship





### **Connect Designed to Address Key Research Priorities**



Emerging exposures



Novel biomarkers, genomics



Cutting-edge methodology




Diverse and special populations

# Cohort Study Design Overview & Recruitment Update



### **Key Study Design Features of Connect**


- ► 200,000 adults across the US
  - ✓ Aged 40-65 years
  - ✓ No history of cancer
  - ✓ Patients or members of partner health care systems
- ► Long-term follow-up
- Serial assessments
- Comprehensive cancer outcomes
- ► Flexible infrastructure for enhancement studies








### Serial Assessments to Observe Longitudinal Changes






### Expansion of recruitment to CPRIT-funded site expected to increase diversity of catchment population






### **Currently, scaling up recruitment**






### **Current Number of Verified Participants and Response Proportion**







### Distribution of Race & Ethnicity (%) Among Connect Verified Participants





### Distributions among Connect participants in comparison with other populations

Demographic/ Risk Factor	Connect Participants	Compared with US Representative Data <sup>1</sup>	Compared with Cohorts of Similar Birth Cohorts <sup>2</sup>
Males	30%		
Gender Minorities	<1%		
Sexual Minorities	7%		
Black	14%		
Hispanic	3%		
Asian/ Pacific Islander	5%		
College graduate or higher	62%		
Income, \$100k+	46%		
Obesity	36%		
Alcohol, never consumed	5%		
Tobacco user, current	8%		

<sup>1</sup>2020 US Census or NHANES; <sup>2</sup>All of Us, CPS-3

### **Participant Engagement**



### **Recruitment Materials & Strategy**

- Value proposition to anchor communications
- Prevention-focused messaging
- Materials designed to engender trust, enthusiasm, and inclusivity
- Monetary and non-monetary incentives
- Active and passive recruitment

# Connect today. Prevent cancer tomorrow.



### **Retention Strategies**

- Candid messaging about participant burden for the long-term
- Responsive communication using multiple channels
- Incentives for retention, such as return of results





### **Ongoing Engagement Strategies**

- Digital engagement
- Regular contact every 6 months beyond those for study activities
- "Study anniversary" mailing
- Monitor real-time metrics to pivot engagement strategy





### **MyConnect Participant App**





### MyConnect Participant App: Communication and Study Activity Hub

#### **Existing Functionality**

Reminders & Communication








**Study Activities** 







Planned Functionality

Return of Results




Mobile/ Wearable Technologies







### **Educational Module before Long Form Consent**







#### **Informed Consent**

In order to join Connect, we need to you to give your informed consent by reviewing the full consent form and electronic health records release form, and signing your name.


### Informed consent form


This is a more detailed explanation of what it means to take part in Connect.

Download an unsigned copy of the consent form



### **Messages and Data Input**






### **Biospecimen Collections**





### **Biospecimen Collections at Recruitment**



	Tubes	Fraction	Tube Type
Buccal	1		Saliva-mouthwash kit
Blood	2	Serum	10ml Red top
	1	Plasma/ buffy coat	10ml Lavender top (EDTA)
	1	Plasma/ buffy coat	10ml Green top (Heparin)
	1	Whole blood	6ml ACD
Urine	1		10ml Urine kit
Tissue			Precursor tissue blocks, if available

No.



### **Biospecimen Collections at Follow-up**

- Timed on average every three years
  - More frequent for participants at higher risk of cancer
- Series of same biospecimens and new types of biospecimens (e.g., liquid biopsy, stool)
- Located at healthcare system, external clinic, home
- Paired with questionnaires and other relevant data collection



### Surveys





### **Baseline Surveys**

### Background and Overall Health

- Background Information
- Medical History
- Family History of Cancer
- Education and Occupation

Medications, Reproductive Health, Exercise, Sleep


- Medications
- Pregnancy History
- Physical Activity
- Sleep

Smoking, Alcohol, Sun Exposure

- Tobacco
- Marijuana
- Alcohol
- Sun Exposure

Where You Live and Work

- Residential History
- Commuting





### **Surveys Accompanying Biospecimen Collection**

#### **Blood & Urine**

- Recent exposures to food, drink, pharmaceuticals
- Reproductive Health
  - Last menstrual period

date

#### Menstrual Cycle

Next menstrual period date

#### Mouthwash

- Oral health and care
- Recent exposures to toothpaste, mouthwash, gum, tobacco
- Permanent teeth lost

#### COVID-19

- Exposure
- Complications
- Long-COVID
- Vaccination



### Planned Follow-up Surveys

#### 6 Months

Diet food frequency questionnaire (DHQ)

#### Within 24 Months

Repeated 24-hour recalls for diet (ASA24) and physical activity (ACT24)

#### 12 Months

Screening,
Quality of life
(PROMIS),
Psychosocial, Social
determinants of
health

#### 2 Years

Baseline exposures repeat assessment, Hair & personal care products,
Napthalene & scented products

#### 3-6 Months Post-Cancer Diagnosis Rapid Case Ascertainment

Cancer Diagnosis Surveys (Symptoms, diagnoses, weight, and medical history)


Quality of life (PROMIS: repeat assessment & patient specific)



### **Data Linkages**

### **Data Linkages**

Cancer registries, virtual tumor registry



Geospatial data (such as outdoor air quality data, other EPA MyEnvironment, WATERS data, US Census)

(such as Medicare, other EHR for participants that leave IHCS)

Mortality (NDI

Health outcomes data (such as HIV registry)



### **Geographic Information**


 Geocode 20-year address histories (collected on baseline survey)

 Enable linkages to datasets for numerous external risk factor and exposure information


Useful for planning ancillary field studies

Add daily movement and travel to exposure information via MyConnect

information via MyConnect







### **Wearable Devices and Apps**

- Connect will have research-grade and consumer-oriented devices available
- Key domains where tech can improve assessment of exposures and risk factors:
  - sleep
  - light at night
  - air pollution
  - physical activity





### **Estimated Outcomes**

### Estimated total number of incident invasive cancers

O-11-11-11-11-11-11-11-11-11-11-11-11-11	Total Number of Expected Incident Cancers		
Cancer site	10 years of follow up	15 years of follow up	
Prostate (males only)	1,951	3,595	
Breast (females only)	1,566	2,553	
Lung & Bronchus	1,151	2,165	
Colorectal	877	1,566	
Melanoma of the Skin	410	681	
Non-Hodgkin Lymphoma	369	649	
Uterine Corpus	345	579	
Urinary Bladder	327	622	
Thyroid	232	356	
Pancreas	221	410	
Leukemia	203	365	
Ovary	146	246	

### **Estimated Total Number of Precursor Lesions**

	Total Number of Expected Precursor Lesions		
Lesions	Retrospective at Baseline	Prospective at 10 Years of Follow Up	
Colorectal Adenomas	5,778	18,311	
Benign Breast Biopsies (females only)	2,339	4,942	
Dysplastic Nevus	2,311	3,779	
Cervical Biopsies (females only)	2,137	2,822	
High-Grade Prostatic Intraepithelial Neoplasia (males only)	238	384	
Lung Nodules	165	349	

## Data System Infrastructure & Digital Tools


Designed to maximize F.A.I.R. principles





### F.A.I.R. Data Ecosystem Makes F.A.I.R. Data

### **Principles**






- Authentication and authorization parameters to enforce governance
- Online governance and instructions for data access (when data available)



Cloud-based data available through governed APIs



Data, metadata, code, tools and infrastructure available through public, versioned, open-source code on <u>GitHub</u>


### Implementation in Connect

- Online, searchable data dictionary
- Map variables to common thesaurus to aid pooling (planned)

https://www.go-fair.org/fair-principles/; https://episphere.github.io/




### Connect Data Ecosystem provides an interoperable infrastructure





#### **Example of Front-End User Interface: MyConnect Participant App**



#### Benefit of Middle Layer of APIs: Pulling from multiple resources

#### **Baseline Recruitment**




- Deidentified data on eligible members/patients
- Verification of consented individuals in MyConnect
- Study activity flags

#### **Study Services**



- Communications, Twilio
- Incentives
- Quest survey tool



#### **Participant-Provided Access**


- Wearable devices: FitBit, air monitors, etc.
- External health care records: Medicare, other EHR for participants that leave partner healthcare systems, etc.

#### Data Linkages



- Health outcomes: cancer registries, virtual tumor registry, NDI mortality, HIV registry
- Geospatial data: outdoor air quality data, other EPA data, US Census

# Quest provides open-source code to render surveys into MyConnect and capture data into Connect's backend data





# Governance & Organizational Structure



#### **Connect Governance**

**Connect Leadership and Coordinating Center** 

#### **Governing Board**

**Stephen Chanock (Chair)** 

#### **Executive Leadership**

#### **Steering Committee**

Chief Scientist (Chair), DCEG Connect Pls, Coordinating Center Leadership, DCEG Associate Directors

#### **Executive Committee**

Chief Scientist (co-Chair), Rotating Site PI (co-Chair), Steering Committee Members, Site PIs, Participant Advisory Board Lead, Support Service Contractor Leads

#### **External Advisory and Review Groups**

#### **International Scientific Advisory Board**

Naomi Allen, Eric Boerwinkle, Julie Buring, Carmen Guerra, Chris Haiman, David Hunter, Roger Milne, Alpa Patel, Karriem Watson

National Cancer Institute (NCI) Board of Scientific Counselors (BSC) – Clinical Sciences and Epidemiology

**Participant Advisory Board (PAB)** 

#### **Connect Leadership and Organization**

#### **Governing Board**

#### **Executive Leadership**

**Steering Committee** 

**Executive Committee** 

#### **Coordinating Center**

Mia Gaudet, Chief Scientist of Connect

#### **Resource Access Committee**

Representatives from the Connect Coordinating Center, Executive Committee, external investigators, study participants, ethics experts, and funding agencies

Ad hoc Expert Review Panels

#### **Subcommittees**

Biospecimens • Questionnaires • Devices Meta-Level Data • Medical Records

Ad hoc Working Groups

# **EpiSphere Data Science & Engineering Research Group**

**Jonas Almeida, Chief Data Scientist** 



## **Connect Resource Development Structure**

#### Subcommittees (standing)

- Guide development of Connect infrastructure and enhancements
- Led by DCEG with NIH investigators
- Report to Steering Committee
- Working Groups (ad hoc)
  - Led by nominator with investigators from NIH, recruitment sites, and scientific community
  - Develop scientific and technical details of proposals and protocols
  - Report to relevant Subcommittees





### **Resource Enhancements**

New questionnaire modules, biospecimens, other sources of data

#### **Connect Resource Building Principles**



Research resource enhanced by scientific community



Balance scientific value with participant burden




Maximize participant privacy and confidentiality



All enhancements grow Connect resources

#### **Connect Resource Enhancement Approval Process**





## Resource Access Principles



#### **Connect Resource Access Principles**



Research resource for scientific community



Broad data sharing policies




Participant privacy and confidentiality



F.A.I.R. data infrastructure

#### Resource Access for All\*



#### **Levels of Data Access**

